OrbusNeich Medical Company Ltd.

OrbusNeich Medical Company Ltd. is a major player in the global medical device manufacturing industry, specializing in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, the company operates in over 70 countries and regions worldwide. It is worth noting that OrbusNeich is the only PCI balloon manufacturer based in China to be among the top 6 players in all major overseas PCI balloon markets such as Japan, Europe, and the U.S. The company holds a significant market share, with an over 50% share of the PCI balloon market in Hong Kong and notable rankings in other key markets. Furthermore, OrbusNeich is active in the development and sale of not only PCI/PTA balloons but also coronary stent products, and it is expanding into neurovascular intervention and structural heart disease areas. With a strong focus on research and development, OrbusNeich owns more than 180 granted patents globally and has developed proprietary, world-leading technologies. These include the Scoreflex NC product, recognized as the world’s smallest profile non-compliant scoring balloon, as well as the proprietary “drug plus antibody” COMBO dual therapy stent and the JADE non-compliant peripheral balloon. The company is listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code 6929. OrbusNeich recently received a significant $200.00M Series B investment on 30 August 2021, with participation from notable investors such as Galaxy Holding Group, Share Capital, Shenzhen Capital Group, CCB International, CICC, and China Merchants Securities. For more information and news, visit OrbusNeich's website at http://www.orbusneich.com/ or follow them on Twitter @OrbusNeich.